Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02709239 · ClinicalTrials.gov registry record · NA
Prenatal DHA and Neurofunctional Development
A NA study of Use and Dose of Prenatal DHA Supplementation, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT02709239 is a NA study of Use and Dose of Prenatal DHA Supplementation that has completed, run by University of Kansas Medical Center. The registered enrollment target is 300 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02709239, a NA study of Use and Dose of Prenatal DHA Supplementation, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn how much DHA to give to mothers in order to provide enough to the baby. Researchers will also learn if there are differences in development of the baby up to 12 months after birth.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT DHA 200mg
- DIETARY_SUPPLEMENT DHA 800mg
Study Locations (1)
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2016-06-01 |
| Est. Completion | 2021-08-16 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02709239
The ClinicalTrials.gov registry entry for NCT02709239 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Use and Dose of Prenatal DHA Supplementation appearing as the primary indexed condition, and to 2 interventions - of which DHA 200mg is the first listed.
NCT02709239 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT02709239 about?
NCT02709239 is a clinical study titled "Prenatal DHA and Neurofunctional Development". The purpose of this study is to learn how much DHA to give to mothers in order to provide enough to the baby. Researchers will also learn if there are differences in development of the baby up to 12 months after birth.
What is the current status of trial NCT02709239?
This trial is currently completed. It is a NA study. The enrollment target is 300 participants. The study started on 2016-06-01. Estimated completion is 2021-08-16.
What conditions does trial NCT02709239 study?
This clinical trial studies the following conditions: Use and Dose of Prenatal DHA Supplementation.
What interventions are being tested in trial NCT02709239?
The interventions under investigation include: DHA 200mg (DIETARY_SUPPLEMENT), DHA 800mg (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02709239?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02709239 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.